Treatment-refractory Dravet syndrome calls for new options
By Whang, byung-woo | translator Alice Kang
24.11.13 05:50:11
가나다라
0
Despite the introduction of medical cannabis, drug-refractory patients still exist, emphasizing the need for a better treatment environment
Despite increased treatment options, a hurdle remains in the reimbursement approval process
Doctors request the authorities’ attention to new options that can manage seizures and comorbidities
Despite increased treatment options for the ultra-rare Dravet syndrome, there are still gaps in care that require attention.
Even with the introduction of medical cannabis, cannabidiol, there are patients who do not respond to the drug, which is why improving access to new options should be considered.
Dravet syndrome is a rare neurological disorder that begins with fever and convulsions within the first year of life, persists into adulthood, and leaves nearly all young patients moderately to severely disabled after each attack.
Although it is known to be a rare disease with an estimated prevalence of 1 to 2 per 10,000 people worldwide, there is no officially inve
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)